Buch, Englisch, 244 Seiten, HC runder Rücken kaschiert, Format (B × H): 175 mm x 250 mm, Gewicht: 629 g
Reihe: Milestones in Drug Therapy
Buch, Englisch, 244 Seiten, HC runder Rücken kaschiert, Format (B × H): 175 mm x 250 mm, Gewicht: 629 g
Reihe: Milestones in Drug Therapy
ISBN: 978-3-7643-0214-6
Verlag: Springer
The field of biomedical research on alcoholism has developed at an unsurpassed speed in recent years. Today new medications and treatment strategies are available and new leads are currently tested in multi-center trials. This book gives a comprehensive overview about different neurotransmitter/peptide systems involved in relapse behavior. The editors - a basic preclinical researcher and a clinical researcher - and some of the most distinguished experts in the field compiled all new available preclinical and clinical data and offer a complete picture on modern relapse prevention. Without a doubt this book provides an entire overview about the topic which will be of interest to the basic researcher, the clinician as well as to the postgraduate and graduate student.
Zielgruppe
Professional/practitioner
Autoren/Hrsg.
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Neurologie, Klinische Neurowissenschaft
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Psychiatrie, Sozialpsychiatrie, Suchttherapie
Weitere Infos & Material
History of prevention of relapse.- How to measure relapse in animals.- How to measure relapse in humans.- Disulfiram (Antabuse®): the first medication to stop drinking.- Naltrexone: preclinical data.- Naltrexone: clinical data.- Acamprosate: preclinical data.- Acamprosate: clinical data.- Serotonergic compounds: preclinical data.- Serotonergic compounds: clinical data.- Opioidergic compounds: preclinical data.- Second generation opioidergic compounds: clinical data.- Dopaminergic compounds: preclinical data.- Dopaminergic compounds: clinical data.- Baclofen: preclinical data.- Baclofen: clinical data.- Cannabinoid receptor antagonists: a perspective.- Neuropeptide Y antagonists: a perspective.- Glutamatergic compounds: a perspective.- Future perspectives on relapse prevention.
